Clinical Trials Logo

Acquired Hemophilia A clinical trials

View clinical trials related to Acquired Hemophilia A.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06461533 Recruiting - Clinical trials for Acquired Hemophilia A

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Start date: June 10, 2024
Phase:
Study type: Observational

This study is a survey in Japan of Susoctocog Alfa (Genetical Recombination) intravenous injection used to treat participants with bleeding events of acquired Haemophilia A (AHA). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from Susoctocog Alfa (Genetical Recombination) intravenous injection and to check if Susoctocog Alfa (Genetical Recombination) intravenous injection improves bleeding events of AHA. During the study, participants with AHA will take Susoctocog Alfa (Genetical Recombination) intravenous injection according to their clinic's standard practice. The study doctors will check for side effects from Susoctocog Alfa (Genetical Recombination) intravenous injection for up to 90 days after the last dose of study drug or until discontinued (varied from participant to participant).

NCT ID: NCT05345197 Recruiting - Clinical trials for Acquired Hemophilia A

Emicizumab in Patients With Acquired Hemophilia A

AHAEmi
Start date: August 31, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).

NCT ID: NCT03700229 Recruiting - Clinical trials for Acquired Hemophilia A

Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A

Start date: October 10, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this prospective study is to determine the efficacy and safety of Rituximab plus Bortezomib in patients with newly diagnosed acquired hemophilia A.